SOURCE: Accelrys


February 18, 2009 11:00 ET

Accelrys Kicks Off Annual User Group Conference

Includes Presentations From Abbott Labs, Baylor College of Medicine, Boeing and Bristol Myers Squibb

SAN DIEGO, CA--(Marketwire - February 18, 2009) - Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific business intelligence software and services, today kicks off its annual User Group Conference being held at the Dana Hotel in San Diego, California from February 18 to 20, 2009. The User Group Conference creates a forum that brings together the global Accelrys community, including customers, partners and employees, to share best practices and expand the application of scientific business intelligence to the scientific community.

The conference will include presentations from customers including:

--  "Pareto Ligand Designer," Jim Metz, Abbott Labs
--  "Automated Image-Based Data Mining for Ultra-High Content Screening,"
    Michael Mancini, Sean Hartig, and Felicity Ashcroft; Baylor College of
--  "Product Development and the Role of Computational Materials," Gerould
    Young, Boeing
--  "E-Novo: An Automated Workflow for Efficient Structure-Based Lead
    Optimization," Brad Pearce, Bristol Myer Squibb

"We are very excited to launch our 2009 Annual User Group Conference," said Todd Johnson, president and CEO of Accelrys. "This conference creates a strong forum for our partners and customers to discuss industry and market trends so that we can better offer solutions that make processes involving scientific information more efficient, enabling companies to better leverage the vast amounts of data they possess. We're honored to have so many distinguished guests sharing their successes and exchanging ideas at our User Group Meeting."

For more information about the 2009 Accelrys User Group Conference, visit

About Accelrys, Inc.

Headquartered in San Diego, California, Accelrys develops scientific business intelligence software and solutions for the life sciences, energy, chemicals, aerospace, and consumer products industries. Customers include many Fortune 500 companies and other commercial entities, as well as academic and government entities. Accelrys offers a vast portfolio of computer-aided design modeling and simulation offerings which assist scientific and research-based organizations in conducting scientific experiments 'in silico' in order to reduce the duration and cost of discovering and developing new drugs and materials. Our scientific business intelligence platform underlies most of our computer-aided design modeling and simulation offerings. Our platform can be used with our products, our competitors' products and our customers' proprietary predictive science products. Its flexibility, ease-of-use and advanced chemical, text and image analysis and reporting capabilities enable our customers to mine, aggregate, analyze and report scientific data from disparate sources, thereby better utilizing scientific data within their organizations. For more information about Accelrys, visit

Forward-Looking Statements

This press release contains forward-looking statements. Such statements, including statements relating to the Company's products, their features, and their impact upon our customers' organizations, are subject to risks and uncertainties including, but not limited to, the risk that our products will not be successfully developed, achieve market acceptance, have the anticipated impact upon our customers' organizations, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and any subsequent interim filings. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.